FDA's generative-AI medical-device discussion paper: comment period closes

What changed

The window for feedback on Considerations for the Regulation of Generative AI-Enabled Medical Devices closed. The paper floats:

• a two-axis risk framework;
• a "competency-based" premarket approach (benchmarking plus clinical confirmation);
• risk-proportionate postmarket monitoring;
• treatment of foundation models and agentic AI.

What this establishes

FDA has collected public input on a possible approach.

What this does not establish

It is not guidance, draft or final, and not a rule. Nothing in it binds a manufacturer.

Next decision point

CDRH's FY2027 guidance agenda (posted Oct 1) lists a generative-AI risk and evidence document as "under construction". It also lists a draft on generative-AI conversational devices for mental disorders on the A-list.

Sources

• FDA GenAI device discussion paper page Primary · 2026-08-18 · checked 2026-10-19
• Regulations.gov docket FDA-2026-N-7874 Primary · checked 2026-10-19
• FDA GenAI discussion paper PDF (Competency-Based Approach, sec. V) Primary · 2026-08-18 · checked 2026-10-20

Related on this site

• Policy §1 (AI scribe flagship)
• R10 (TGA)
• R17 (CDRH list)
• Records ledger

Register: the record store · record id fda-genai-device-discussion-paper-comments-close-2026-10-19 · SOURCE-VERIFIED · HUMAN REVIEW PENDING.